Drug Information

Drug General Information
Drug ID
D05ODU
Former ID
DIB010524
Drug Name
Belerofon
Synonyms
IFNa; IFN-beta
Indication HCV infection [ICD9: 070.4, 070.5, 070.70; ICD10:B17.1, B18.2] Phase 1 [551542]
Company
Nautilus Biotech
Target and Pathway
Target(s) IFN-alphaR Target Info Modulator [550137]
KEGG Pathway Cytokine-cytokine receptor interaction
PI3K-Akt signaling pathway
Osteoclast differentiation
Toll-like receptor signaling pathway
Jak-STAT signaling pathway
Natural killer cell mediated cytotoxicity
Hepatitis C
Hepatitis B
Measles
Influenza A
Herpes simplex infection
NetPath Pathway TCR Signaling Pathway
Leptin Signaling Pathway
PANTHER Pathway Inflammation mediated by chemokine and cytokine signaling pathway
Pathway Interaction Database Downstream signaling in na&#xef
Reactome Interferon alpha/beta signaling
Regulation of IFNA signaling
WikiPathways Toll-like receptor signaling pathway
Interferon type I signaling pathways
Interferon alpha/beta signaling
Regulation of toll-like receptor signaling pathway
Osteoclast Signaling
References
Ref 551542Nautilus Biotech Receives FDA Approval for Phase 1 Clinical Trial in the USA for Oral Belerofon(R), its Long-Lasting, Interferon-Alpha Drug. Nautilus Biotech. MAY 14, 2007.
Ref 550137WO patent application no. 2009,0153,36, Controlled release interferon drug products and treatment of hcv infection using same.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.